Table 5.
Uni- and multivariate analysis of risk factors affecting the relapse-free survival (RFS) of HAL patients
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Age (year) | 0.987 | 0.944, 1.032 | 0.568 | |||
| Sex (M/F) | 0.543 | 0.110, 2.671 | 0.452 | |||
| Smoking (Y/N) | 1.337 | 0.297, 6.022 | 0.705 | |||
| Brinkman index (number per day × years) | 1.000 | 0.999, 1.001 | 0.905 | |||
| Elevated AFP (Y/N) | 0.994 | 0.279, 3.540 | 0.992 | |||
| Maximum diameter (cm) | 1.110 | 1.002, 1.229 | 0.045 | 1.109 | 1.000, 1.228 | 0.049 |
| AJCC 8th Edition stage (early/advanced tumor) | 2.015 | 0.591, 6.866 | 0.263 | |||
| Pathomorphological classification (typical/atypical) | 0.683 | 0.282, 1.653 | 0.398 | |||
| Pathological differentiation (well-/moderately-/poorly-differentiated) | 2.145 | 0.445, 10.352 | 0.342 | |||
| Therapeutic method (Surg/Chemo/Others) | 1.868 | 0.990, 3.525 | 0.054 | |||
Notes: The variables with P value <0.1 in univariate analysis were included in multivariate analysis. AFP, alpha-fetoprotein; Chemo, chemotherapy-based strategy; F, female; HAL, hepatoid adenocarcinoma of the lung; M, male; N, no; Surg, surgery-based strategy; Y, yes.